Amit Munshi has more than $300M and a startup CSO out to pioneer next-gen RNA therapeutics. Once again, he’s thinking big

Amit Munshi had to beg off when he was first introduced to the idea of running an MPM BioImpact stealth player named ReNAgade Therapeutics. He …

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Amit Mun­shi has more than $300M and a start­up CSO out to pi­o­neer next-gen RNA ther­a­peu­tics. Once again, he’s think­ing big